通过CT定量的身体成分：弥漫性大B细胞淋巴瘤患者的化疗毒性和预后 - Suppr

Suppr

超能文献

Body composition quantified by CT: chemotherapy toxicity and prognosis in patients with diffuse large B-cell lymphoma.

作者信息

An Yueming, Zhao Weijia, Zuo Liping, Fan Jinlei, Chen Zhiyu, Jin Xinjuan, Du Peng, Han Pei, Zhao Wei, Yu Dexin

机构信息

Qilu Hospital of Shandong University, Jinan, China.

出版信息

Abdom Radiol (NY). 2025 Mar;50(3):1392-1402. doi: 10.1007/s00261-024-04608-x. Epub 2024 Sep 26.

DOI:10.1007/s00261-024-04608-x

PMID:39400587

Abstract

摘要

相似文献

Body composition quantified by CT: chemotherapy toxicity and prognosis in patients with diffuse large B-cell lymphoma.通过CT定量的身体成分：弥漫性大B细胞淋巴瘤患者的化疗毒性和预后

Abdom Radiol (NY). 2025 Mar;50(3):1392-1402. doi: 10.1007/s00261-024-04608-x. Epub 2024 Sep 26.

Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy.人体成分分析作为预测弥漫性大 B 细胞淋巴瘤患者接受 R-CHOP 免疫化疗毒性和预后的指标。

Curr Oncol. 2021 Mar 23;28(2):1325-1337. doi: 10.3390/curroncol28020126.

Role of body composition and metabolic parameters extracted from baseline F-FDG PET/CT in patients with diffuse large B-cell lymphoma.基线 F-FDG PET/CT 提取的体成分和代谢参数在弥漫性大 B 细胞淋巴瘤患者中的作用。

Ann Hematol. 2023 Oct;102(10):2779-2789. doi: 10.1007/s00277-023-05379-z. Epub 2023 Aug 2.

F-FDG PET/CT metabolic parameter changes to assess vascular inflammatory response in patients with diffuse large B-cell lymphoma.采用F-FDG PET/CT代谢参数变化评估弥漫性大B细胞淋巴瘤患者的血管炎症反应

BMC Med Imaging. 2025 Mar 7;25(1):81. doi: 10.1186/s12880-025-01617-0.

The prognostic value of bone marrow retention index and bone marrow-to-liver ratio of baseline 18F-FDG PET/CT in diffuse large B-cell lymphoma.基线 18F-FDG PET/CT 中骨髓滞留指数和骨髓-肝脏比值对弥漫性大 B 细胞淋巴瘤的预后价值。

Eur Radiol. 2024 Apr;34(4):2500-2511. doi: 10.1007/s00330-023-10150-z. Epub 2023 Oct 9.

CT-based body composition in diffuse large B cell lymphoma patients: changes after treatment and association with survival.基于 CT 的弥漫性大 B 细胞淋巴瘤患者的身体成分：治疗后的变化与生存的关系。

Radiol Med. 2023 Dec;128(12):1497-1507. doi: 10.1007/s11547-023-01723-5. Epub 2023 Sep 26.

Expression of activation-induced cytidine deaminase is associated with a poor prognosis of diffuse large B cell lymphoma patients treated with CHOP-based chemotherapy.活化诱导胞嘧啶脱氨酶的表达与接受基于CHOP化疗的弥漫性大B细胞淋巴瘤患者的不良预后相关。

J Cancer Res Clin Oncol. 2016 Jan;142(1):27-36. doi: 10.1007/s00432-015-2001-7. Epub 2015 Jun 16.

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.利用分子谱分析预测弥漫性大B细胞淋巴瘤化疗后的生存率。

N Engl J Med. 2002 Jun 20;346(25):1937-47. doi: 10.1056/NEJMoa012914.

[Prognostic value of PET-CT in patients with diffuse large B-cell lymphoma].[PET-CT在弥漫性大B细胞淋巴瘤患者中的预后价值]

Zhonghua Zhong Liu Za Zhi. 2014 Dec;36(12):923-7.

Therapeutic comparison of chemotherapy and surgery for early stage diffuse large B-cell gastric lymphoma.早期弥漫性大B细胞胃淋巴瘤化疗与手术的疗效比较

Yonsei Med J. 2007 Dec 31;48(6):942-8. doi: 10.3349/ymj.2007.48.6.942.

本文引用的文献

Skeletal muscle index impacts the treatment outcome of elderly patients with diffuse large B cell lymphoma.骨骼肌指数影响老年弥漫性大 B 细胞淋巴瘤患者的治疗效果。

Hematol Oncol. 2024 Jan;42(1):e3252. doi: 10.1002/hon.3252.

Epidemiology and etiology of diffuse large B-cell lymphoma.弥漫性大B细胞淋巴瘤的流行病学与病因学

Semin Hematol. 2023 Nov;60(5):255-266. doi: 10.1053/j.seminhematol.2023.11.004. Epub 2023 Nov 27.

Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands.复发或难治性弥漫性大B细胞淋巴瘤患者的治疗与转归：荷兰一项当代全国性基于人群的研究

Blood Cancer J. 2024 Jan 4;14(1):3. doi: 10.1038/s41408-023-00970-z.

Sex differences in abdominal visceral fat composition and metabolism as predictors of DLBCL prognosis: A retrospective cohort study.腹部内脏脂肪组成和代谢的性别差异作为弥漫性大 B 细胞淋巴瘤预后的预测因素：一项回顾性队列研究。

Eur J Radiol. 2024 Jan;170:111205. doi: 10.1016/j.ejrad.2023.111205. Epub 2023 Nov 21.

Abdominal adipose tissue and type 2 diabetic kidney disease: adipose radiology assessment, impact, and mechanisms.腹部脂肪组织与 2 型糖尿病肾病：脂肪影像学评估、影响及机制。

Abdom Radiol (NY). 2024 Feb;49(2):560-574. doi: 10.1007/s00261-023-04062-1. Epub 2023 Oct 17.

Radiol Med. 2023 Dec;128(12):1497-1507. doi: 10.1007/s11547-023-01723-5. Epub 2023 Sep 26.

Ann Hematol. 2023 Oct;102(10):2779-2789. doi: 10.1007/s00277-023-05379-z. Epub 2023 Aug 2.

Diffuse Large B-Cell Lymphoma and Related Entities.弥漫性大 B 细胞淋巴瘤及相关疾病。

Dtsch Arztebl Int. 2023 Apr 28;120(17):289-296. doi: 10.3238/arztebl.m2023.0035.

How I treat diffuse large B-cell lymphoma.我如何治疗弥漫性大 B 细胞淋巴瘤。

ESMO Open. 2023 Feb;8(1):100750. doi: 10.1016/j.esmoop.2022.100750. Epub 2023 Jan 10.

Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options.弥漫性大B细胞淋巴瘤（DLBCL）：患者早期管理及新出现的治疗选择

Onco Targets Ther. 2022 Dec 6;15:1481-1501. doi: 10.2147/OTT.S326632. eCollection 2022.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验